Other Non-Current Liabilities
Eli Lilly Other Non-Current Liabilities increased by 2.9% to $4.09B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 78.5%, from $2.29B to $4.09B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 18.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.80B | $1.75B | $1.64B | $1.71B | $1.78B | $1.85B | $1.82B | $1.82B | $1.95B | $1.91B | $2.24B | $2.27B | $2.47B | $2.24B | $3.48B | $2.29B | $2.34B | $3.78B | $3.97B | $4.09B |
| QoQ Change | — | -3.0% | -6.0% | +4.2% | +4.0% | +3.9% | -1.6% | -0.1% | +7.1% | -2.3% | +17.5% | +1.3% | +8.8% | -9.4% | +55.4% | -34.2% | +2.5% | +61.1% | +5.1% | +2.9% |
| YoY Change | — | — | — | — | -1.0% | +6.0% | +10.9% | +6.3% | +9.5% | +2.9% | +22.8% | +24.6% | +26.6% | +17.5% | +55.3% | +0.8% | -5.1% | +68.6% | +14.1% | +78.5% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other non-current liabilities?
- Eli Lilly (LLY) reported other non-current liabilities of $4.09B in Q1 2026.
- How has Eli Lilly's other non-current liabilities changed year-over-year?
- Eli Lilly's other non-current liabilities increased by 78.5% year-over-year, from $2.29B to $4.09B.
- What is the long-term trend for Eli Lilly's other non-current liabilities?
- Over 5 years (2020 to 2025), Eli Lilly's other non-current liabilities has grown at a 18.4% compound annual growth rate (CAGR), from $1.71B to $3.97B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.